Publications

Newsletters

Selected articles

  • Scaling Up Programmatic Management of Drug-Resistant Tuberculosis: A Prioritized Research Agenda
  • Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs - worldwide, 2000-2004. Morbidity and Mortality Weekly Report, 2006, 55(11):301-305.
  • Nathanson E et al. Multidrug-resistant tuberculosis management in resource-limited settings. Emerging Infectious Diseases. 2006 Sep;12(9):1389-97.
  • Furin J J et al. Occurrence of serious adverse events in patients receiving community based therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2001; 5: 648-655.
  • Gupta R et al. Responding to market failures in tuberculosis control. Science. 2001;293:1048-105.
  • Gupta R et al. Increasing Transparency in Partnerships for Health - Introducing the Green Light Committee. Tropical Medicine and International Health. 2002;7(11):970-976.
  • Gupta R et al. Scaling up treatment for HIV/AIDS: lessons learned from multidrug-resistant tuberculosis. Lancet. 2004;363:320-324.
  • Kim JY et al. From multidrug-resistant tuberculosis to DOTS expansion and beyond: making the most of a paradigm shift. Tuberculosis, 2003, 83:59-65.
  • Laserson KF et al. Speaking the Same Language: Treatment Outcome Definitions for Multidrug-Resistant Tuberculosis. Int J Tuberc Lung Dis. 2005 Jun;9(6):640-5
  • Leimane V et al. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet. 2005;365:318-26.
  • Mitnick C et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 2003; 348: 119-128.
  • Mukherjee JS et al. Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet. 2004;363:474-81.
  • Nathanson E et al. Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative. Int J Tuberc Lung Dis. 2004;8:1382-1384.